Alebund Pharmaceutical
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $550M
Overview
Developing novel therapeutics for metabolic and rare diseases through targeted metabolic pathway modulation.
MetabolicRare Disease
Technology Platform
A proprietary platform focused on the identification and modulation of key targets within metabolic pathways to develop therapeutics for dysregulated metabolic conditions.
Funding History
1Total raised:$550M
PIPE$550M
Opportunities
Significant unmet need and potential for orphan drug designations and premium pricing in rare metabolic diseases.
Risk Factors
Clinical development risks are high given the small patient populations and complex biology of metabolic disorders.
Competitive Landscape
Competes with large pharma rare disease divisions and specialized biotechs like Ultragenyx and BridgeBio in niche metabolic disorders.